Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Tenet Healthcare logo
Tenet HealthcareTHC
-$145M-704%
Pfizer logo
PfizerPFE
-$117.25M+54.2%
Procter & Gamble logo
Procter & GamblePG
$648M+620%
Merck & Co. logo
Merck & Co.MRK
$27.5M-39.6%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$2M-14.0%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$611.36B+67.2%
Enterprise value$644.66B+62.0%
P/E29.1×+12.9×
P/S6.3×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's change in AP?
Johnson & Johnson (JNJ) reported change in AP of -$3.92B in Q1 2026.
How has Johnson & Johnson's change in AP changed year-over-year?
Johnson & Johnson's change in AP decreased by 84.4% year-over-year, from -$2.13B to -$3.92B.
What is the long-term trend for Johnson & Johnson's change in AP?
Over 3 years (2021 to 2025), Johnson & Johnson's change in AP has grown at a -0.8% compound annual growth rate (CAGR), from $2.44B to $2.38B.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.